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This paper utilised two surveillance datasets collected by the respiratory (Tuberculosis section) and 
HIV departments in the National Infections Service at Public Health England. In light of the work 
involved in collecting and linking these two datasets, and designing a study utilising both of them, 
we have listed 13 authors for this paper. 
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Abstract and keywords 1 
Objectives 2 
Tuberculosis (TB) is common in people living with HIV (PLHIV), leading to worse clinical 3 
outcomes including increased mortality. We investigated risk factors for developing TB 4 
following HIV diagnosis. 5 
Design 6 
Adults aged ≥15 years first presenting to health services for HIV care in England, Wales or 7 
Northern Ireland from 2000-2014 were identified from national HIV surveillance data and 8 
linked to TB surveillance data. 9 
Methods 10 
We calculated incidence rates for TB occurring >91 days after HIV diagnosis and investigated 11 
risk factors using multivariable Poisson regression. 12 
Results 13 
95,003 adults diagnosed with HIV were followed for 635,591 person-years (PY); overall 14 
incidence of TB was 344/100,000PY (95% confidence interval 330-359). TB incidence was high 15 
for people who acquired HIV through injecting drugs (PWID; men 876 [696-1,104], women 605 16 
[528-593]) and black Africans born in high TB incidence countries (644 [612-677]). The adjusted 17 
incidence rate ratio (IRR) for TB amongst PWID was 4.79 [3.35-6.85] for men and 6.18 [3.49-18 
10.93] for women, compared to men who have sex with men. The adjusted IRR for TB in black 19 
Africans from high-TB countries was 4·27 (3·42-5·33), compared to white UK-born individuals. 20 
Lower time-updated CD4 count was associated with increased rates of TB. 21 
Conclusions 22 
PWID had the greatest risk of TB; incidence rates were comparable to those in black Africans 23 
from high TB incidence countries. Most TB cases in PWID were UK-born, and likely acquired TB 24 
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through transmission within the UK. Earlier HIV diagnosis and quicker initiation of ART should 25 
reduce TB incidence in these populations. 26 
Keywords 27 
HIV, tuberculosis, co-infection, observational study, cohort studies, risk factors 28 
 29 
  30 
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Introduction 31 
Tuberculosis (TB) and HIV are leading causes of morbidity and mortality. Globally, in 2014 32 
there were 1.2 million new cases of TB in people living with HIV (PLHIV), accounting for one in 33 
eight TB diagnoses.[1] TB was responsible for one in three HIV-related deaths in 2014. 34 
In England, Wales and Northern Ireland, 25% of AIDS-defining illnesses from 2001-2010 were 35 
TB.[2] The rate of TB disease in PLHIV in the UK was estimated as 328/100,000 person-years 36 
(PY) between 1996 and 2005 (excluding patients diagnosed with TB and HIV simultaneously 37 
[within 91 days]),[3] and 669/100,000PY across all groups 2007-2011.[4] Estimated TB 38 
incidence in the general population is much lower; 10/100,000 population in 2015.[5]  39 
Previous studies in the UK have found higher rates of TB in PLHIV who acquired HIV abroad, or 40 
had black African or Indian/Pakistani/Bangladeshi ethnicity, than in white and UK-born 41 
populations.[3, 6] TB incidence decreased with increasing CD4 count at HIV diagnosis, and was 42 
lower for individuals on antiretroviral therapy (ART). However, [6] was limited in its 43 
implications for UK TB-HIV control as it was restricted to heterosexuals and did not adjust for 44 
time on ART, which is known to be linked to TB incidence.[4] It also included patients 45 
diagnosed simultaneously with TB and HIV, many of whom are only diagnosed with HIV as a 46 
result of their TB diagnosis.[6] Furthermore, the UK-CHIC study [3] did not provide estimates of 47 
TB incidence in PWID.  48 
TB incidence in HIV-positive people who inject drugs (PWID) in the 1980s and 1990s was very 49 
high;[7] however the link between TB and HIV-positive PWID in the ART era is less clear. Five 50 
cohort studies found TB rates were elevated by a factor of 1.7-4.4 when compared to men who 51 
have sex with men (MSM) or people who do not inject drugs,[8-12] whilst one cohort[13] and 52 
one cross-sectional study[14] found no significantly increased risk. In the UK, PWID are 53 
typically diagnosed with HIV late[15] and have high rates of death,[16, 17] despite good levels 54 
of ART coverage (90%), similar to other risk groups.[18] No recent studies in the UK have 55 
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investigated the risk of TB for PWID. This study aimed to investigate risk factors for developing 56 
TB following HIV diagnosis, including HIV acquisition by injecting drug use, to address the 57 
paucity of evidence in resource-rich countries in the ART era. 58 
Methods 59 
Study population 60 
Adults (aged 15 years or older) notified to Public Health England (PHE)’s HIV and AIDS 61 
Reporting System (HARS), first presenting with HIV to health services in England, Wales and 62 
Northern Ireland between 2000 and 2014 were included. HARS comprises four linked data 63 
sources: reports of all new HIV/AIDS diagnoses and deaths, national laboratory data for CD4 64 
count, annual reporting of demographic and clinical information of PLHIV from all national 65 
clinics, and death reports from the Office of National Statistics.[17, 19] 66 
Outcome: TB disease diagnosed from 2000-2014 67 
TB cases included both culture-confirmed and presumptive (clinical and radiological signs, 68 
including a response to specific therapy) diagnoses. 69 
UK HIV and TB surveillance are undertaken separately, necessitating data linkage to analyse 70 
co-infection. TB cases across England, Wales and Northern Ireland are reported to the PHE’s 71 
Enhanced Tuberculosis Surveillance (ETS) system. To identify PLHIV with TB disease, HARS and 72 
ETS data were linked using a probabilistic matching algorithm (adapted from [20]), with 73 
supplementary deterministic matching to accept/reject borderline matches.[21] 74 
Incident TB was defined as TB disease notified to ETS or reported to HARS as a new AIDS-75 
defining illness, that was diagnosed >91 days after HIV diagnosis. TB cases diagnosed within 91 76 
days of HIV diagnosis were considered simultaneous diagnoses, to differentiate patients who 77 
were not aware of their HIV infection prior to their TB diagnosis. TB cases diagnosed >91 days 78 
before HIV were considered existing disease. A 91 day threshold for defining simultaneous 79 
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diagnoses was a pragmatic choice to account for delays in diagnosis and reporting, and to 80 
exclude ART-induced unmasking immune reconstitution inflammatory syndrome. 81 
Exposure variables 82 
We included demographic (age at HIV diagnosis, sex, ethnicity, country of birth, TB incidence in 83 
country of birth, route of HIV infection, year of HIV diagnosis, index of multiple deprivation 84 
[IMD] decile) and clinical (viral load at first presentation, and time-updated CD4 count and ART 85 
initiation) exposure variables. IMD score deciles represent relative levels of deprivation of 86 
income, employment, health, education, housing and services, crime and living environment 87 
for small areas in England and Wales, where 1=most deprived and 10=least deprived.[22, 23] 88 
Composite variables were created combining ethnicity and country of birth or sex and 89 
infection route due to mutually exclusive combinations (e.g. being a woman and a MSM is 90 
impossible) and known associations. As a proxy TB exposure, countries of birth outside the UK 91 
were grouped by TB incidence; ‘high incidence’ was defined as >40 cases/100,000 adult 92 
population in 2013. The most recent IMD data for each country between 2000 and 2014 were 93 
used; 2010 for England and 2014 for Wales. 94 
Statistical Analysis 95 
Data were analysed in Stata version 13.1. Descriptive analyses of the cohort were undertaken. 96 
To investigate risk factors for developing TB, we calculated incidence rates of TB per 100,000PY 97 
follow-up and assessed TB incidence over time using Nelson-Aalen cumulative hazard plots. 98 
We estimated incidence rate ratios using univariable and multivariable Poisson regression 99 
models, offset by follow-up time, Cox regression was precluded as our data did not satisfy the 100 
proportional hazards assumption for key variables such as route of HIV infection. Individuals 101 
diagnosed with TB ≤91 days after HIV diagnosis were excluded to investigate subsequent TB. 102 
Follow-up began 92 days from date of HIV diagnosis or first presentation to UK health services 103 
and ended on the date of TB diagnosis, death, or 31/12/2014, whichever was earliest. CD4 104 
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count and ART initiation were included as time-updated covariates. Incidence rates for 105 
different CD4 strata were calculated using the number of days from each CD4 count to the 106 
date of the next CD4 count for each patient. To compare incidence between ART-naïve 107 
patients and patients who had initiated ART, we split each patient’s follow-up period at the 108 
date they first initiated ART to calculate the duration of ART-naïve person-time, and person-109 
time having initiated ART. 110 
Potential confounders and effect modifiers were prospectively identified.[24] Our causal 111 
framework determined that viral load should be excluded from the multivariable model 112 
because of the potential for causal loops between viral load and CD4 count, which could not 113 
be adequately accounted for in the data available. We excluded patients missing data on one 114 
or more variables. Linearity (of age, CD4 count and year of HIV diagnosis) and statistical 115 
interactions (between ART status and CD4 count) were assessed using likelihood-ratio tests. As 116 
we were not investigating a single “main” exposure variable, there were no confounders in the 117 
traditional sense, and therefore the multivariable model was informed by a causal inference 118 
framework defined a priori. To assess the likely impact of missing data, we compared the 119 
distributions of age, sex, route of HIV infection, CD4 count and ethnicity/country of birth for 120 
cases with missing vs. complete data on infection route, CD4 count, IMD score and country of 121 
birth. Statistical interactions were considered significant at P<0.05. All stated confidence 122 
intervals are two-sided 95% confidence intervals. 123 
Planned sensitivity analyses investigated the impact of using a 6-month threshold (182 days) 124 
for simultaneous diagnosis; excluding weaker matches between HARS and ETS; and excluding 125 
people who acquired HIV infection through mother-to-child transmission, as the dataset only 126 
contained adults and so individuals infected through this route could be missing 15 years 127 
follow-up. 128 
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Ethics, consent and permissions 129 
This analysis was approved by the UCL student Research Ethics Committee (5683/001). PHE 130 
has authority under the Health and Social Care Act 2012 to hold and analyse national 131 
surveillance data for public health and research purposes. 132 
Role of the funding source 133 
The funding source had no involvement in the study design; the collection, analysis and 134 
interpretation of the data; the writing of the report or the decision to submit the paper for 135 
publication. 136 
Results 137 
Description of co-infected patients 138 
Between 2000 and 2014, 102,202 adults were newly diagnosed with HIV, among whom 5,649 139 
(6%) had TB. 3,103 (55%) were simultaneously diagnosed with TB and HIV, 2,187 (39%) 140 
developed TB after >91 days and 359 (6%) were diagnosed with TB first (Table 1).  141 
Of people with TB who acquired HIV infection through heterosexual sex, over half were 142 
diagnosed simultaneously with TB and HIV; 60% for men and 54% for women. In contrast, 143 
more TB cases in MSM and PWID were diagnosed more than 91 days after diagnosis of HIV 144 
infection (51% and 54%, respectively). The proportion of TB cases occurring after HIV diagnosis 145 
was highest in white, UK-born individuals (179/359, 48%) and those born in low TB incidence 146 
countries (116/245, 47%); these two groups comprise 38% of the cohort. 147 
Incidence of TB following HIV diagnosis 148 
95,003 adults were TB-free 92 days after presenting for HIV care, with a total of 635,591PY 149 
follow-up. Median age at HIV diagnosis was 34 years (inter-quartile range [IQR] 28-42) and 150 
median CD4 count was 340 cells/µl (IQR 170-527). 95% of patients had >1 CD4 count (median 151 
14). 152 
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Overall TB incidence was 344/100,000PY (95% CI: 330-359, Table 1). The probability of 153 
developing TB was highest in the year following HIV diagnosis and then decreased (Figure 1a). 154 
Incidence was high in PWID (men 876/100,000 [696-1,104/100,000]; women 605/100,000 155 
[386-949/100,000]) and heterosexuals (men 598/100,000 [555-645/100,000], women 559 156 
[528-593/100,000]), particularly compared with MSM (111/100,000 [98-126/100,000]). The 157 
largest differences in cumulative probability of TB diagnosis between PWID, black Africans 158 
from high-TB incidence countries and MSM were in the first two years following HIV diagnosis; 159 
the rate of diagnosis remained relatively constant across all groups thereafter (Figure 1b). 160 
TB incidence increased with decreasing time-updated CD4 count, from 139/100,000 (123-161 
157/100,000) for those with CD4 count ≥500 cells/µl to 2,788/100,000 (2,368-3,282/100,000) 162 
for those with CD4 count <50 cells/µl. TB incidence was 511/100,000 (484-539/100,000) in 163 
people who had never received ART (26% of all PY) compared to 228/100,000 (213-164 
243/100,000) in people who had (74% of PY). TB incidence was higher for PWID who had never 165 
initiated ART (1,478/100,000 [95% CI 1,157-1,888/100,000] than for black Africans from high-166 
TB incidence countries who had never initiated ART (991/100,000 [929-1,058/100,000]) 167 
although incidence rates following ART initiation were similar in both groups (384/100,000 168 
[264-560/100,000] for PWID versus 421 [389-456/100,000] for black Africans). TB incidence 169 
was highest in those living in areas of England and Wales with the lowest decile of IMD score 170 
(485/100,000 [437-537/100,000]). 171 
Factors associated with developing TB disease 172 
62,684 individuals with complete case data and a TB-free follow-up period of >91 days 173 
following HIV diagnosis were included in the time-to-event analysis. There were a total of 174 
414,714 PY of follow-up (median follow-up 7·1 years, IQR 3·6-10·4), during which there were 175 
1,591 TB diagnoses (Table 2). The median duration of follow-up was 7.3 years (IQR 3.9-10.4) 176 
for patients who did not develop TB, whilst patients who did develop TB did so in a median of 177 
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0.2 years (IQR 0.1-0.5). Black African patients born in high-TB countries had a slightly higher 178 
median follow-up period of 8.2 (4.7-11.0) years, compared to 6.3 (3.1-9.8) for MSM and 6.5 179 
(3.4-9.8) for PWID, as black Africans were more likely to be diagnosed earlier in the study 180 
period than PWID or MSM. 181 
All exposures were included in the multivariable Poisson regression model (Table 2), except 182 
viral load and IMD decile. IMD decile was excluded as there was a high degree of missing data 183 
and no association with the outcome in a multivariable model (supplementary tables 1-3). CD4 184 
count and age at HIV diagnosis were treated as categorical variables (tests for linearity 185 
P<0·001, P=0·005, respectively), year of HIV diagnosis was treated as a linear variable 186 
(P>0.05).There was a statistically significant interaction between time-updated CD4 count and 187 
time-updated ART status (P<0·001). 188 
Compared to MSM, PWID had increased rates of TB (incidence rate ratio [IRR] for men 5·47 189 
[95% confidence interval 4·07-7·35]; women 4·59 [2·75-7·67]). Rates were also higher in those 190 
infected through heterosexual sex (men 1·70 [1·38-2·10]; women 1·86 [1·51-2·29]). UK-born 191 
black Africans (1·97 [1·10-3·51]) and people of other ethnicities (1·92 [1·29-2·84]) were 192 
associated with increased incidence rates versus white UK-born individuals, as were those 193 
born in high TB incidence countries (black African 4·27 [3·42-5·33], white 2·19 [1·53-3·15], 194 
other ethnicities 3·36 [2·57-4·39]). 195 
Overall, and within each stratum of CD4 count, TB rates were greatly reduced in individuals 196 
who had received ART compared to those who had not (Table 3). When stratifying by ART 197 
initiation status, lower time-updated CD4 count was strongly associated with increased TB 198 
rates (Table 4). For individuals who had never initiated ART, the IRR for TB increased with 199 
decreasing CD4 count to 6·42 [4·87-8·46] for 0-49 cells/µl cf. ≥500 cells/µl. The increased risk 200 
at low CD4 count was higher in individuals who had initiated ART, with an IRR of 44·21 [30·90-201 
63·24] for 0-49 cells/µl, cf. ≥500 cells/µl. 202 
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In a post-hoc analysis of patients who had initiated ART, we found that those who developed 203 
TB were more likely to have discontinued ART at their last clinic visit (27%, versus 6% of those 204 
without TB, P<0.001, Supplementary table 4). ART initiation rates and time from the most 205 
recent clinic visit to the end of the study were similar for MSM, heterosexuals and PWID. 206 
There was no substantial difference in the age, sex, ethnicity/country of birth, route of HIV 207 
infection or CD4 count of patients with missing data on any of the following variables: route of 208 
HIV infection, CD4 count, IMD decile and country of birth. Patients with missing route of 209 
infection were less likely to be diagnosed with TB; however there were no substantial 210 
differences for patients missing data on any other variable.  211 
Sensitivity analysis 212 
Sensitivity analyses were conducted as follows: (1) excluding 241 individuals who acquired HIV 213 
infection through mother-to-child transmission, (2) excluding 595 individuals with TB whose 214 
probabilistic matching scores (linking to their HIV record) were in the lowest quartile, (3) 215 
excluding 137 individuals with TB who were matched to their HIV record using the three 216 
lowest-ranked deterministic criteria, (4) excluding 424 individuals diagnosed with TB 92-182 217 
days after HIV diagnosis, (5) including IMD score and excluding data on 12,432 individuals 218 
missing IMD score. All analyses provided consistent results with the main model 219 
(supplementary tables 1-3). 220 
Discussion 221 
People who acquired HIV infection through injecting drug use (largely UK-born patients) had a 222 
high risk of TB following their HIV diagnosis, with incidence rates comparable to those in black 223 
Africans born in high TB incidence countries; almost five-fold more than MSM after accounting 224 
for other factors including starting ART. Consistent with previous research,[3, 6] declining CD4 225 
count was associated with higher TB rates. 226 
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This study benefits from the very large national HIV-positive cohort, providing comprehensive 227 
results for England, Wales and Northern Ireland. The algorithm linking patients with TB and 228 
HIV utilises ethnicity, year and country of birth; all variables with very high completeness: 229 
97·3%, 99·9% and 90·5% respectively. 230 
We found no substantial differences in the demographics or proportion of TB in patients 231 
missing data on each of these variables; however patients missing data on one variable were 232 
more likely to have other missing data. Additionally, patients missing data for multiple 233 
variables were less likely to be linked to a TB notification and therefore we may have 234 
underestimated TB incidence rates; it is likely that the low incidence of TB in patients with 235 
“unknown” route of HIV infection is a symptom of this and patients with extensive missing 236 
data may be more likely to be from populations at high risk for TB. Additionally, the record 237 
linkage algorithm is less sensitive to non-English names,[20] therefore we may have 238 
underestimated TB incidence in foreign populations. 239 
One limitation was missing CD4 count data for approximately a third of patients, who were 240 
therefore excluded from the risk factor analysis. This is partly due to difficulties linking data, 241 
and partly because some large hospitals do not supply CD4 count data to HARS. However, we 242 
found no evidence that patients with missing CD4 count data were systematically different to 243 
our analysis cohort. As our sample size remained very large, and there was no evidence that 244 
patients missing data were systematically different, we chose not to use multiple imputation 245 
due to the complexity of the dataset as a result of using time-updated CD4 count and ART 246 
initiation. Data were available on ART discontinuation, but were of poor quality and could not 247 
be included in the model. Consequently we may have underestimated the association between 248 
starting ART and lower TB incidence by assuming all individuals remained on treatment for the 249 
duration of our study. 250 
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Individuals entered the study cohort 92 days after HIV diagnosis or first presentation to UK 251 
health services; therefore we may have underestimated TB incidence in people diagnosed 252 
abroad who were at risk prior to entering the UK, as we would have missed TB cases diagnosed 253 
during the initial period following HIV diagnosis when TB incidence is highest. A recent study of 254 
PLHIV had 18% loss to follow-up over 4 years, and 14% of TB cases diagnosed >91 days after 255 
HIV diagnosis were in these patients.[4] As TB and HIV are sometimes treated (and usually 256 
reported) separately in the UK, dropping out of HIV care does not prevent notification of a TB 257 
diagnosis. We therefore used passive censoring, continuing follow-up until 31/12/2014 rather 258 
than the date last seen for HIV care. Consequently, migration out of the UK may mean we 259 
underestimated TB incidence. 260 
A limitation of the Poisson regression model was censoring due to competing risks, specifically 261 
deaths from non-TB causes. However, few patients died (3%) and median time to death was 262 
3.4 years, substantially longer than median time to TB diagnosis (1·8 years); therefore any 263 
impact of censoring is likely to be minimal. 264 
While PWID represented <2% of PLHIV, they accounted for 3% of TB cases in this population 265 
and >4% of cases diagnosed >91 days after HIV diagnosis. TB incidence in PWID in our study 266 
(876/100,000PY in men and 605/100,000 in women) was substantially higher than that in a 267 
cohort of German PLHIV,[25] possibly because this cohort utilises active rather than passive 268 
follow-up and excluded patients who did not present to care for 6 months or more, who may 269 
be more likely to develop TB disease than patients who remain engaged with care. PWID are 270 
typically diagnosed with HIV late,[18] have slower rates of linkage to care and lower rates of 271 
viral suppression,[26] all of which may contribute to increased risk of TB. We found ART 272 
initiation and the time from the last clinic visit to the end of the study were comparable for 273 
MSM, heterosexuals and PWID; and that PWID did not have higher rates of ART 274 
discontinuation at their last clinic visit prior to study end (Supplementary Table 4). 275 
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Consequently, it seems high rates of TB among PWID are caused by difficulties in linking to 276 
care and not lack of engagement with health services once linked. Many PWID have other co-277 
morbidities which may cause immunosuppression, make HIV care more challenging, or be 278 
associated with increased risk of TB.[27] Additionally there are high rates of alcoholism and 279 
homelessness, and living in hostels is common.[28] These, in addition to injecting drugs in 280 
shared social settings, may drive close mixing of people with similar risk factors for TB disease, 281 
driving transmission. High rates of smoking may also have impacts on both local lung immunity 282 
and TB transmission. Further studies are needed to explore the impact of these factors and to 283 
design effective interventions. BHIVA guidelines currently recommend testing and treating 284 
LTBI among PLHIV using criteria based on CD4 count, time on ART and country of birth.[29] As 285 
the incidence of TB among PWID was comparable to that of black African patients born in 286 
countries with high TB incidence, we suggest that additionally screening and treating PWID for 287 
LTBI should be considered. 288 
The majority of PWID were white (51%) and born in the UK or low TB incidence countries 289 
(72%). It is therefore likely that most TB in this group was acquired in the UK, meaning these 290 
cases may be preventable by diagnosing HIV sooner and ensuring prompt ART initiation. We 291 
could also do more to diagnose TB cases sooner; the impact of active case finding in PLHIV 292 
should be evaluated. In contrast, heterosexuals were typically black African (61%) and born in 293 
high TB incidence countries (69%), both populations which also have high rates of TB among 294 
HIV-negative people. Consequently, they are likely to have acquired TB abroad, limiting our 295 
ability to prevent these TB infections if they present with clinical TB at the time of HIV 296 
diagnosis.[30] As >60% of heterosexuals were diagnosed with TB simultaneously or prior to 297 
HIV diagnosis, greater efforts to diagnose these HIV infections and initiate ART would reduce 298 
TB in this population. A greater focus on screening and treating latent TB infection (LTBI) could 299 
also prevent these cases.[31] There is little data available on the prevalence of LTBI and the 300 
use of preventive therapy among PLHIV in the UK. Rates of LTBI screening and uptake of 301 
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preventive therapy vary substantially between HIV clinics,[32, 33] and a survey of UK HIV 302 
healthcare providers providing care to 90% of PLHIV in the UK found that only 54% offered 303 
LTBI screening and preventive therapy.[34] Health economics evaluations would be useful to 304 
determine the most effective screening measures for these populations. 305 
Over half of all TB cases (55%) were diagnosed simultaneously with HIV infection, and of the 306 
39% diagnosed later, the probability of a TB diagnosis was highest in the first year following 307 
HIV diagnosis (Figure 1). This suggests that TB disease is largely the result of TB infection 308 
acquired prior to HIV diagnosis. This could result from late diagnosis of existing active TB, 309 
particularly in migrants who have recently moved to the UK from high-burden countries and 310 
whose TB is largely attributable to reactivation of remotely acquired infection.[35] 311 
Additionally, the incidence of TB amongst migrants decreases with time since entry to the UK, 312 
as new TB infection is less likely in the UK than their country of origin. Other factors which 313 
could explain this trend are increased surveillance for opportunistic infections following HIV 314 
diagnosis, or “unmasking-type” immune reconstitution inflammatory syndrome as a 315 
consequence of ART. Whilst TB incidence was lower after the first year since HIV diagnosis 316 
(Table 1), 25% of all TB cases occurred more than one year after HIV diagnosis. These cases can 317 
certainly be attributed to reactivation of LTBI and could be preventable with LTBI treatment. 318 
Patients who had initiated ART had greatly reduced rates of TB compared to those who had 319 
not (Table 3); however time-updated CD4 count and ART initiation status interacted within our 320 
model. Higher rate ratios for TB at low CD4 count in people on ART may be attributable to late 321 
ART start (i.e. long periods of low CD4 count prior to initiating ART and then little time on ART 322 
prior to TB diagnosis), or due to ART discontinuation. The SMART trial demonstrated an 323 
association between stopping ART and increased risk of opportunistic disease and death.[36] 324 
Our post-hoc analysis of patients who had started ART demonstrated that patients who went 325 
on to develop TB were more likely to have discontinued ART at their last study visit than 326 
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individuals who remained TB-free (Table 5). This suggests ART discontinuation could leave 327 
patients at risk of new TB disease. 328 
In England, Wales and Northern Ireland, PLHIV who acquired HIV by injecting drugs had higher 329 
rates of TB after their HIV diagnosis than MSM, comparable to black Africans born in countries 330 
with high TB incidence. High rates of TB in PWID are likely to result from transmission within 331 
the UK. ART is highly protective against TB, but the majority of TB diagnoses were in people 332 
who have never started ART. ART discontinuation rates were much higher in people who 333 
subsequently developed TB than those who did not. Quicker initiation of ART, as per the 334 
recently updated BHIVA guidelines,[37] and improving retention in care and ART continuation 335 
should decrease incident TB in PLHIV. 336 
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Figures 471 
Figure 1: Cumulative hazard plot of the probability of developing TB from >91 days following 472 
HIV diagnosis 473 
  474 
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Tables 475 
Table 1: TB diagnoses in people notified with HIV from 2000 to 2014 in England, Wales and Northern Ireland, and the incidence rates of TB in people who 476 
were diagnosed with TB >91 days following HIV diagnosis. 477 
  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Total 102,202 5,649 (5.5) 359 (6) 3,103 (55) 2,187 (39) 635,591 344 (330 - 359) 247 (234 - 260) 
Route of HIV infection 
       
 
MSM 35,879 (35.1) 462 (1.3) 31 (7) 195 (42) 236 (51) 212,844 111 (98 - 126) 86 (74 - 100) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Heterosexual men 18,738 (18.3) 2,013 (10.7) 127 (6) 1,205 (60) 681 (34) 113,802 598 (555 - 645) 402 (365 - 443) 
Heterosexual women 30,489 (29.8) 2,815 (9.2) 167 (6) 1,520 (54) 1,128 (40) 201,644 559 (528 - 593) 404 (376 - 434) 
Men who inject drugs 1,453 (1.4) 132 (9.1) 5 (4) 55 (42) 72 (55) 8,216 876 (696 - 1,104) 660 (499 - 873) 
Women who inject 
drugs 532 (0.5) 35 (6.6) 1 (3) 15 (43) 19 (54) 3,138 605 (365 - 945) 526 (295 - 868) 
Blood/Tissue transfer 505 (0.5) 58 (11.5) 6 (10) 31 (53) 21 (36) 2,928 717 (468 - 1,100) 527 (288 - 883) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Mother-to-child 253 (0.2) 15 (5.9) 1 (7) 4 (27) 10 (67) 863 1,159 (556 - 2,131) 836 (307 - 1,819) 
Unknown≠ 14,353 (14.0) 119 (0.8) 21 (18) 78 (66) 20 (17) 92,155 22 (14 - 34) 13 (7 - 24) 
Ethnicity/Country of 
birth 
       
 
White, UK-born 27,320 (26.7) 359 (1.3) 24 (7) 161 (45) 174 (48) 160,488 108 (93 - 126) 84 (70 - 100) 
Black African, UK-born 947 (0.9) 51 (5.4) 6 (12) 25 (49) 20 (39) 5,556 360 (232 - 558) 260 (151 - 448) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Other ethnicity, UK-
born 2,687 (2.6) 72 (2.7) 6 (8) 26 (36) 40 (56) 14,948 268 (196 - 365) 217 (151 - 313) 
Ethnicity unknown, 
UK-born 403 (0.4) 3 (0.7) 0 (0) 3 (100) 0 (0) 544 0 (0 - 678)‡ 0 (0 - 876)‡ 
Born in low-TB 
incidence country 11,551 (11.3) 245 (2.1) 11 (4) 118 (48) 116 (47) 65,376 177 (148 - 213) 125 (99 - 157) 
White, born in high-TB 
7,461 (7.3) 126 (1.7) 4 (3) 71 (56) 51 (40) 47,593 107 (81 - 141) 84 (61 - 116) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
incidence country 
Black African, born in 
high-TB incidence 
country 35,035 (34.3) 3,877 (11.1) 223 (6) 2,142 (55) 1,512 (39) 234,853 644 (612 - 677) 454 (426 - 483) 
Other ethnicity, born 
in high-TB incidence 
country 6,756 (6.6) 518 (7.7) 52 (10) 311 (60) 155 (30) 35,614 435 (372 - 509) 290 (236 - 356) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Ethnicity unknown, 
born in high-TB 
incidence country 1,140 (1.1) 13 (1.1) 2 (15) 10 (77) 1 (8) 7,556 13 (0 - 74)‡ 15 (0 - 81) 
White, country of 
birth unknown 3,065 (3.0) 52 (1.7) 4 (8) 31 (60) 17 (33) 23,968 71 (41 - 114) 54 (28 - 95) 
Other ethnicity, 
country of birth 
unknown 4,226 (4.1) 300 (7.1) 23 (8) 181 (60) 96 (32) 33,093 290 (237 - 354) 210 (164 - 268) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Both Unknown≠ 1,611 (1.6) 33 (2.0) 4 (12) 24 (73) 5 (15) 6,002 83 (27 - 194) 39 (5 - 141) 
Age at HIV diagnosis 
(years) 
       
 
15-24 11,513 (11.3) 437 (3.8) 25 (6) 173 (40) 239 (55) 73,647 325 (286 - 368) 260 (224 - 302) 
25-34 38,910 (38.1) 2,227 (5.7) 129 (6) 1,121 (50) 977 (44) 261,955 373 (350 - 397) 280 (260 - 302) 
35-44 31,894 (31.2) 1,944 (6.1) 133 (7) 1,147 (59) 664 (34) 199,946 332 (308 - 358) 232 (211 - 255) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
45-64 18,357 (18.0) 973 (5.3) 64 (7) 619 (64) 290 (30) 93,708 309 (276 - 347) 183 (156 - 214) 
65+ 1,479 (1.4) 68 (4.6) 8 (12) 43 (63) 17 (25) 5,764 295 (172 - 472) 99 (172 - 472) 
CD4 count at HIV diagnosis† (incidence rates are calculated for time-updated CD4) 
   
 
≥500 20,153 (19.7) 381 (1.9) 30 (8) 88 (23) 263 (69) 187,994 139 (123 - 157) 122 (106 - 139) 
350-499 14,801 (14.5) 455 (3.1) 34 (7) 133 (29) 288 (63) 114,505 259 (231 - 290) 270 (241 - 304) 
200-349 16,282 (15.9) 861 (5.3) 61 (7) 388 (45) 412 (48) 81,579 527 (480 - 579) 454 (407 - 506) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
100-199 9,514 (9.3) 1,039 (10.9) 79 (8) 613 (59) 347 (33) 24,933 1,356 (1,219 - 1,508) 785 (673 - 916) 
50-99 5,039 (4.9) 718 (14.2) 35 (5) 525 (73) 158 (22) 6,247 2,209 (1,870 - 2,610) 1,072 (817 - 1,407) 
0-49 8,731 (8.5) 1,241 (14.2) 63 (5) 956 (77) 222 (18) 5,166 2,788 (2,368 - 3,282) 891 (648 - 1,224) 
Unknown≠ 27,682 (27.1) 954 (3.4) 57 (6) 400 (42) 497 (52) - - - 
Viral load at diagnosis 
(copies/ml) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
≤200 13,951 (13.7) 580 (4.2) 51 (9) 311 (54) 218 (38) 63,098 345 (303 - 395) 227 (190 - 270) 
>200 58,824 (57.6) 3,735 (6.3) 229 (6) 2,050 (55) 1,456 (39) 339,621 428 (407 - 451) 305 (286 - 325) 
Unknown≠ 29,427 (28.8) 1,334 (4.5) 79 (6) 742 (56) 513 (38) 232,872 221 (202 - 241) 170 (153 - 188) 
Ever started ART 
(time-updated) 
       
 
No 32,207 (31.5) 809 (2.5) - - 1336§ 261,662 511 (484 - 539) 337 (314 - 362) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Yes 69,995 (68.5) 4,840 (6.9) - - 851§ 373,929 228 (213 - 243) 188 (174 - 203) 
IMD decile 
       
 
1 13,498 (13.2) 900 (6.7) 64 (7) 470 (52) 366 (41) 75,516 485 (437 - 537) 343 (301 - 390) 
2 15,075 (14.8) 920 (6.1) 66 (7) 510 (55) 344 (37) 86,339 398 (358 - 443) 286 (251 - 327) 
3 12,746 (12.5) 688 (5.4) 53 (8) 385 (56) 250 (36) 72,760 344 (304 - 389) 247 (212 - 288) 
4 9,150 (9.0) 474 (5.2) 29 (6) 273 (58) 172 (36) 52,758 326 (281 - 379) 222 (183 - 268) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
5 6,732 (6.6) 336 (5.0) 22 (7) 191 (57) 123 (37) 37,961 324 (272 - 387) 235 (189 - 293) 
6 5,233 (5.1) 253 (4.8) 18 (7) 134 (53) 101 (40) 29,630 341 (280 - 414) 238 (186 - 304) 
7 3,870 (3.8) 164 (4.2) 10 (6) 89 (54) 65 (40) 21,596 301 (236 - 384) 233 (174 - 312) 
8 3,304 (3.2) 140 (4.2) 6 (4) 83 (59) 51 (36) 17,934 290 (221 - 381) 207 (147 - 291) 
9 2,809 (2.7) 110 (3.9) 7 (6) 64 (58) 39 (35) 15,846 246 (180 - 337) 163 (108 - 245) 
10 2,217 (2.2) 97 (4.4) 3 (3) 52 (54) 42 (43) 11,925 352 (260 - 477) 274 (190 - 394) 
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  HIV cases TB cases       
 
 
Total 
Prior to HIV 
diagnosis 
Simultaneous with 
HIV diagnosis Following HIV diagnosis   
  
n (column %) n (row %) n (row %) n (row %) n (row %) 
PY follow-up 
Incidence rate* (95% CI) 
Incidence rate after 
1 year from HIV 
diagnosis* (95% CI) 
Unknown≠ 27,568 (27.0) 1,567 (5.7) 81 (5) 852 (54) 634 (40) 213,326 297 (274 - 321) 217 (197 - 238) 
* Incidence is given per 100,000 population aged ≥15 years, per year. † Incidence rates are calculated for time-updated CD4 count. ≠ Unknown strata includes both 478 
unknown and missing data. ‡One-sided, 97.5% CI. §Of the 5,649 PLHIV who got TB, 809 never initiated ART. However, of the 2,187 who got TB >91 days after their HIV 479 
infection, 1,336 had not initiated TB at the time of their HIV diagnosis. ART: anti-retroviral therapy, CI: confidence interval, IMD: index of multiple deprivation, MSM: 480 
men who have sex with men, PWID: people who inject drugs, PY: person-years, TB: tuberculosis. 481 
 482 
  483 
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Table 2: Univariable and multivariable incidence rate ratios from Poisson regression of factors associated with incident TB disease (>91 days after HIV 484 
diagnosis) among PLHIV in England, Wales and Northern Ireland from 2000 to 2014 485 
      Univariable Multivariable 
  TB cases PY IRR (95% CI) IRR (95% CI) 
Route of HIV infection 
    
MSM 184 172,708 1.00 (P<0.001) 1.00 (P<0.001) 
Male heterosexual 474 82,460 5.40 (4.55 - 6.40) 1.70 (1.38 - 2.10) 
Female heterosexual 837 148,391 5.29 (4.51 - 6.21) 1.86 (1.51 - 2.29) 
Male PWID 61 5,895 9.71 (7.27 - 12.97) 5.47 (4.07 - 7.35) 
Female PWID 16 2,514 5.97 (3.58 - 9.95) 4.59 (2.75 - 7.67) 
Blood/Tissue transfer 14 2,251 5.84 (3.39 - 10.05) 2.70 (1.55 - 4.71) 
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Mother-to-child 5 494 9.51 (3.91 - 23.11) 2.80 (1.13 - 6.97) 
Ethnicity/Country of birth 
    
White, UK-born 134 127,453 1.00 (P<0.001) 1.00 (P<0.001) 
Black African, UK-born 13 4,317 2.86 (1.62 - 5.06) 1.97 (1.10 - 3.51) 
Other ethnicity, UK-born 31 12,040 2.45 (1.66 - 3.62) 1.92 (1.29 - 2.84) 
Ethnicity unknown, UK-born 0 252 † † 
Born in low-TB incidence country 98 53,647 1.74 (1.34 - 2.25) 1.33 (1.02 - 1.73) 
White, born in high-TB incidence 
country 
38 12,606 2.87 (2.00 - 4.11) 2.19 (1.53 - 3.15) 
Black African, born in high-TB 
incidence country 
1,093 148,017 7.02 (5.87 - 8.40) 4.27 (3.42 - 5.33) 
Other ethnicity, born in high-TB 105 22,219 4.50 (3.48 - 5.80) 3.36 (2.57 - 4.39) 
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incidence country 
Ethnicity unknown, born in high-
TB incidence country 
1 323 2.95 (0.41 - 21.07) 1.35 (0.19 - 9.71) 
White, country of birth unknown 12 15,491 0.74 (0.41 - 1.33) 0.52 (0.29 - 0.94) 
Other ethnicity, country of birth 
unknown 
66 18,348 3.42 (2.55 - 4.59) 1.60 (1.17 - 2.20) 
CD4 count 
    
≥500 259 185,719 1.00 (P<0.001) * 
350-499 293 113,185 1.86 (1.57 - 2.19) 
 
200-349 427 80,443 3.81 (3.26 - 4.44) 
 
100-199 332 24,367 9.77 (8.30 - 11.49) 
 
50-99 137 6,093 16.12 (13.11 - 
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19.83) 
0-49 143 4,905 
20.90 (17.04 - 
25.64)  
Ever on ART 
    
No 928 107,477 1.00 (P<0.001) * 
Yes 663 307,237 0.25 (0.23 - 0.28) 
 
Viral load at diagnosis 
    
≤200 154 43,347 1.00 (P=0.006) - 
>200 1,063 261,249 1.15 (0.97 - 1.36) 
 
Age at HIV diagnosis 
    
15-24 169 48,805 0.95 (0.79 - 1.13) 0.92 (0.77 - 1.10) 
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25-34 714 170,957 1.14 (1.02 - 1.28) 1.06 (0.94 - 1.19) 
35-44 477 130,441 1.00 (P<0.001) 1.00 (P=0.332) 
45-64 220 61,028 0.99 (0.84 - 1.16) 1.11 (0.95 - 1.31) 
≥65 11 3,484 0.86 (0.47 - 1.57) 0.92 (0.51 - 1.68) 
Year of HIV diagnosis 
    
(for each year increase from 
2000) 
1,591 414,714 0.98 (0.97 - 1.00) 1.02 (1.00 - 1.04) 
   
P=0.036 P=0.014 
IMD decile (England and Wales 
only)     
1 264 51,685 1.00 (P<0.001) - 
2 269 63,391 0.83 (0.70 - 0.98) 
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3 193 54,955 0.69 (0.57 - 0.83) 
 
4 127 38,159 0.65 (0.53 - 0.81) 
 
5 83 26,725 0.61 (0.48 - 0.78) 
 
6 78 20,986 0.73 (0.57 - 0.94) 
 
7 47 15,254 0.60 (0.44 - 0.82) 
 
8 38 12,644 0.59 (0.42 - 0.83) 
 
9 24 10,743 0.44 (0.29 - 0.66) 
 
10 32 8,326 0.75 (0.52 - 1.09)   
 486 
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62,684 PLHIV were included in this analysis; 32,319 were excluded from the model due to missing data on ethnicity and country of birth, route of HIV infection, CD4 487 
count or age at HIV diagnosis. Viral load was not included in the multivariable model due to collinearity with CD4 count and ART status. *Interaction present between 488 
time-updated CD4 count and time-updated ART status, see Table 4 and Table 3. †Not calculated as numerator was zero. ART: anti-retroviral therapy, CI: confidence 489 
interval, IMD: index of multiple deprivation, MSM: men who have sex with men, PWID: people who inject drugs, PY: person years, IRR: incidence rate ratio, TB: 490 
tuberculosis. 491 
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Table 3: Multivariable Poisson regression of the association between time-updated ART status and TB disease, stratified by CD4 count, among PLHIV in 494 
England, Wales and Northern Ireland from 2000 to 2014 495 
  CD4 count (cells/µl)           
 
≥500 350-499 200-349 100-199 50-99 0-49 
Ever on ART IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) 
No 1·00 1·00 1·00 1·00 1·00 1·00 
Yes 0·07 (0·05 - 0·10) 0·14 (0·11 - 0·18) 0·21 (0·17 - 0·25) 0·32 (0·26 - 0·40) 0·35 (0·25 - 0·49) 0·49 (0·35 - 0·69) 
Incidence rate ratios derived from multivariable Poisson regression of the association between time-updated ART status and TB disease, stratified by CD4 count. Model 496 
adjusted for the variables in the multivariable model in Table 2. 62,684 PLHIV were included in this analysis; 32,319 were excluded from the model due to missing data 497 
on ethnicity and country of birth, route of HIV infection, CD4 count or age at HIV diagnosis. ART: anti-retroviral therapy, CI: confidence interval, IRR: incidence rate 498 
ratio, TB: tuberculosis. 499 
  500 
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Table 4: Multivariable Poisson regression of the association between time-updated CD4 501 
count and TB disease, stratified by ART status, among PLHIV in England, Wales and Northern 502 
Ireland from 2000 to 2014 503 
  Ever on ART 
 
No Yes 
CD4 count (cells/µl) IRR (95% CI) IRR (95% CI) 
≥500 1·00 1·00 
350-499 1·28 (1·06 - 1·55) 2·51 (1·77 - 3·56) 
200-349 2·22 (1·84 - 2·66) 6·37 (4·66 - 8·72) 
100-199 4·74 (3·79 - 5·93) 21·21 (15·59 - 28·85) 
50-99 7·07 (5·26 - 9·51) 34·29 (24·10 - 48·77) 
0-49 6·42 (4·87 - 8·46) 44·21 (30·90 - 63·24) 
Incidence rate ratios derived from multivariable Poisson regression of the association between time-504 
updated CD4 count and TB disease, stratified by ART status. 62,684 PLHIV were included in this 505 
analysis; 32,319 were excluded from the model due to missing data on ethnicity and country of birth, 506 
route of HIV infection, CD4 count or age at HIV diagnosis. Model adjusted for the variables in the 507 
multivariable model in Table 2. ART: anti-retroviral therapy, CI: confidence interval, IRR: incidence 508 
rate ratio, TB: tuberculosis. 509 
 510 
 511 
 512 
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